Ascend Laboratories LLC Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
April 6, 2023FDA Approves Omisirge (omidubicel-onlv) Cell Therapy for Patientswith Blood Cancers to Reduce Risk of Infection Following Stem CellTransplantation
April 17, 2023April 17, 2023 - IntelGenx Corp. has announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's RizaFilm® VersaFilm® 505(b)(2) new drug application (NDA) for the treatment of acute migraine.
RizaFilm® is a proprietary oral thin film formulation of rizatriptan benzoate, the active ingredient in Merck & Co.'s Maxalt® . The global migraine drugs market was valued at nearly $3 billion in 2021 and is expected to reach nearly $11 billion by 2030, representing a compound annual growth rate of 15.6%.
In December 2018, IntelGenx entered into a definitive licensing, development, and supply agreement with Gensco® Pharma ("Gensco") for the exclusive commercialization of RizaFilm® in the United States. Under the terms of the agreement, IntelGenx is entitled to receive royalty payments based on net profits of RizaFilm® ; and is eligible to receive pre-specified payments upon the achievement of certain regulatory and commercial milestones.